Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1
The experimentally established mechanism targets of Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.38 |
| ▸ | KDM4A | O75164 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.38 |
| ▸ | TET3 | O43151 | 1/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lactic Acid SCHEMBL13505613 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL7026852 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL4263083 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL419437 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL41708 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL4261279 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL3845012 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL5269783 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL2286708 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL15008846 | 0.97 | TP53 (0.65) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118217226-A | Photo-thermal composite hydrogel with adjustable slow release performance and preparation method thereof | 西北有色金属研究院 | 2024-06-21 | — | — | CN | claimed |
| CN-118217226-A | Photo-thermal composite hydrogel with adjustable slow release performance and preparation method thereof | 西北有色金属研究院 | 2024-06-21 | — | — | CN | disclosed |
| US-10632079-B2 | Microspheres having core/shell structure | OTSUKA PHARMACEUTICALS CO., LTD. (JP) | 2020-04-28 | — | — | US | disclosed |
| EP-3479839-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPTHALMIC CONDITIONS | Stealth Peptides International, Inc. (MC) | 2019-05-08 | — | — | EP | disclosed |
| US-20180296630-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS | STEALTH BIOTHERAPEUTICS INC. | 2018-10-18 | — | — | US | disclosed |
| EP-3281634-A1 | METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS | Stealth Peptides International, Inc. (MC) | 2018-02-14 | — | — | EP | disclosed |
| US-20160361377-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS | STEALTH BIOTHERAPEUTICS INC. | 2016-12-15 | — | — | US | disclosed |
| EP-3078384-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS | Stealth Peptides International, Inc. (MC) | 2016-10-12 | — | — | EP | disclosed |
| EP-2351574-B1 | PROMOTER FOR REGENERATION OF TENDON-BONE JUNCTION TISSUE OR LIGAMENT-BONE JUNCTION TISSUE | KRINGLE PHARMA INC (JP) | 2016-08-24 | — | — | EP | disclosed |
| EP-1765295-B2 | A PROCESS FOR PRODUCING A SUSTAINED-RELEASE MICROCAPSULE | TAKEDA PHARMACEUTICAL (JP) | 2015-09-09 | — | — | EP | disclosed |
| EP-0647449-A1 | Sustained-release preparation of anti-endothelin substance | Takeda Chemical Industries, Ltd. (JP) | 1995-04-12 | — | — | EP | disclosed |
| EP-0601799-A1 | Sustained-release preparation | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-06-15 | — | — | EP | disclosed |
| EP-0582459-A2 | Production of microcapsules of water-soluble drugs | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-02-09 | — | — | EP | disclosed |
| US-5202352-A | Antitumor agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-04-13 | — | — | US | disclosed |
| EP-0535937-A1 | Prolonged release microparticle preparation and production of the same | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-04-07 | — | — | EP | disclosed |
| EP-0256726-B1 | ENCAPSULATION OF TRH OR ITS ANALOG | Takeda Chemical Industries, Ltd. (JP) | 1992-10-07 | — | — | EP | disclosed |
| EP-0470569-A1 | Intravascular embolizing agent containing angiogenesis inhibiting substance | Takeda Chemical Industries, Ltd. (JP) | 1992-02-12 | — | — | EP | disclosed |
| EP-0429245-A2 | A therapeutic agent for central nervous diseases | Takeda Chemical Industries, Ltd. (JP) | 1991-05-29 | — | — | EP | disclosed |
| EP-0256726-A2 | Encapsulation of TRH or its analog | Takeda Chemical Industries, Ltd. (JP) | 1988-02-24 | — | — | EP | disclosed |
| US-4612364-A | EVAPORATION OF HALOGEN SOLVENT | TAKEDA CHEMICAL INDUSTRIES (JP) | 1986-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361377-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS | ADM2, ARG1, IAPP | TP53 2307/4885OR51E2 3094/4885CYP1A2 4874/4885 |
| US-20180296630-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS | ADM2, ARG1, IAPP | TP53 2307/4885OR51E2 3094/4885CYP1A2 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.